Chimeric Therapeutics Ltd
CHM
Company Profile
Business description
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.
Contact
62 Lygon Street
Level 3, Carlton South
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,021.90 | 60.20 | 0.76% |
| CAC 40 | 7,285.86 | 44.11 | -0.60% |
| DAX 40 | 21,205.86 | 105.16 | -0.49% |
| Dow JONES (US) | 39,241.64 | 427.75 | -1.08% |
| FTSE 100 | 8,275.66 | 0.06 | 0.00% |
| HKSE | 21,395.14 | 338.16 | 1.61% |
| NASDAQ | 16,301.85 | 5.31 | -0.03% |
| Nikkei 225 | 34,377.60 | 457.20 | 1.35% |
| NZX 50 Index | 12,118.99 | 51.07 | 0.42% |
| S&P 500 | 5,296.73 | 21.03 | 0.40% |
| S&P/ASX 200 | 7,819.10 | 60.20 | 0.78% |
| SSE Composite Index | 3,280.34 | 4.34 | 0.13% |